Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Feasibility, outcomes and challenges of CAR-T cell therapy as advanced or earlier line of treatment for B-cell non-Hodgkin lymphomas: A multicenter national study

View Full Paper
Ask AI
Bookmark
Share

Authors

PDPanagiotis DolgyrasITIfigeneia TzannouMLMaria Liga

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals CAR-T therapy improves progression-free survival and overall survival in B-cell lymphomas, suggesting effective real-world implementation.

Key Points

  • Overall survival after CAR-T therapy was 61.1% with a median follow-up of 12.3 months, highlighting its potential effectiveness.
  • Adverse events included cytokine release syndrome in 12.3% and immune effector cell-associated neurotoxicity syndrome in 15.2% of patients.
  • Bridging therapy prior to CAR-T infusion resulted in partial response in 21 patients and complete response in 25 patients, indicating potential benefits.
  • Chimeric antigen receptor therapy showed significant correlation between complete response and improved outcomes, suggesting treatment optimization is crucial.

Cite This Study

Dolgyras et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df4ahttps://doi.org/10.1182/blood-2025-3716
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis2025
  2. 2CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party2025 · 1 citations
  3. 3Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma2025
  4. 4Recent trends in the management of relapsing/refractory diffuse large B-cell lymphoma: A systematic review of the literature2025
  5. 5Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025